Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

August 23, 2005 08:30 ET

Webcast Alert: Resverlogix Corporation Presentation at Informed Investors Biotechnology, Healthcare, Pharmaceuticals Investor Forum to be Webcast on Thursday, August 25, 2005, 12:00 pm ET

CALGARY, ALBERTA--(CCNMatthews - Aug. 23, 2005) - Resverlogix Corporation (TSX:RVX) will present at the following forum:

What: Resverlogix Corporation (TSX:RVX) will give a presentation at Informed Investors Biotechnology, Healthcare, Pharmaceuticals On-line Investors Forum.

The keynote presentation will be from Dr. Adam K. Noah, Research Analyst with Granite Financial Group

When: August 25, 2005 @12:00 PM Eastern Time

Where: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493

How: Live over the Internet-Simply log on to the web at the address above.



Contacts: Donald McCaffrey, President & CEO,
don@resverlogix.com, 403-254-9252 ext. 223

Kenneth Lebioda, Vice President Business & Market Development,
ken@resverlogix.com , 403-254-9252 ext. 227


If you are unable to attend the live event, the forum will be archived and available via the Informed Investors website at http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493

NEXVAS™ Technology: The primary focus for Resverlogix is the development of new technology designed to control cholesterol related diseases such as atherosclerosis (the buildup of plaque in the arteries). Existing drugs control the level of LDL ("bad cholesterol") in the body and thus slow atherosclerosis. Resverlogix's NEXVAS™ program is developing proprietary technology that stimulates the body to produce ApoA1 protein, the primary component of HDL, which results in increased levels of HDL ("good cholesterol"). ApoA1/HDL has been proven to not just arrest but reverse atherosclerosis by reducing existing cholesterol deposits. Activating the body to enhance ApoA1 levels is the simplest physiological or natural approach to regulating HDL.

Cardiovascular disease is the leading cause of death in industrialized countries. The drugs that are currently used to control cholesterol can only slow the progress of atherosclerosis, and yet they are the biggest selling drugs in the world with a combined market of some U.S. $30 billion annually. Resverlogix's ApoA1 technology has the potential to capture and expand much of this market.

For a more detailed explanation about NEXVAS™ technology, please access the animation on the company website at http://resverlogix.com.

Resverlogix Corporation is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's NEXVAS™ Program applies advanced medical research to develop therapies that increase high-density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The company's second technology program, TGF-beta Shield™, utilizes an immunomodulating therapy to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies to prolong and enhance human life.

Source: Resverlogix Corporation

Contact Information